Research paperRapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform
Introduction
The growth of solid tumors beyond a diameter of 1–2 mm critically depends on the formation of a supporting stroma of newly formed blood vessels (Folkman, 1985). Tumor endothelial cells, stromal fibroblasts (activated fibroblast or myofibroblasts) and/or vascular pericytes acquire a phenotype different from that of normal stromal cells (Rettig et al., 1992, Christian et al., 2008) and express tumor vascular markers (TVM). TVM provide attractive targets for antibody-based tumor diagnosis and therapy (St Croix et al., 2000, Marty et al., 2006, Teicher, 2007, Rouleau et al., 2008) due to i) the relative stability of TVM-expressing cells comparing to tumor cells; ii) neovasculature essential function for tumor maintenance, as demonstrated by the widespread necrosis of solid tumor after destruction of their blood vessels (Hinnen and Eskens, 2007); iii) neovasculature leaky capillaries that permit circulating antibodies and antibody conjugates to easily access TVM.
Endosialin/Tumor Endothelial Marker 1 (TEM1 or CD248) is a TVM and a type I transmembrane protein which comprises an 80.9 kDa protein core modified by extensive sialylated O-linked glycosylation that gives rise to an approximately 175 kDa mature glycoprotein (Christian et al., 2001). Endosialin/TEM1 was originally discovered by an anti-fibroblast monoclonal antibody (FB5) as a glycoprotein expressed by the pericytes and myofibroblasts associated with tumor vasculature (MacFadyen et al., 2005, Christian et al., 2008, Rouleau et al., 2008) as well as by tumor-associated vascular endothelial cells in various human cancers (Rettig et al., 1992, Davies et al., 2004, Rmali et al., 2005, Becker et al., 2008), including ovarian cancer (Conejo-Garcia et al., 2005). Endosialin/TEM1 plays a unique role in tumor progression as a promoting factor of tumor angiogenesis (Bagley et al., 2008), proliferation, migration and metastasis through interaction with matrix proteins such as fibronectin, collagen type I and IV (Tomkowicz et al., 2007) and Mac-2 BP/90K (Becker et al., 2008). Importantly, mice without functional Tem1 gene present a striking reduction in tumor growth, invasiveness, and metastasis after tumor transplantation to abdominal sites (Nanda et al., 2006). Taken together, these results suggest that targeting Endosialin/TEM1 for diagnostic and/or therapy could provide a valuable strategy against cancer.
Isolation of antigen-specific antibodies has been achieved through a variety of methods, including screening of phage- and yeast-display recombinant antibody (scFv) libraries (Vaughan et al., 1996, Feldhaus et al., 2003, Paschke, 2006, Scholler et al., 2006, Scholler et al., 2008a, Scholler et al., 2008b, Bergan et al., 2007). Yeast display recently emerged as an efficient alternative strategy due to the advantages it offers over prokaryotic systems, including faster and more controlled flow cytometry-based selection compared to solid phase panning (Feldhaus et al., 2003, Bergan et al., 2007); a highly efficient sampling of the immune antibody repertoire (Bowley et al., 2007); post-translational modifications (glycosylation) due to the eukaryotic expression; and absence of scFv-induced growth bias because scFv are not displayed during the amplification step, when yeast multiply. Yet, transfer of scFv from displayed to secreted forms has often resulted in loss of antigen specificity and/or affinity, requiring additional time-consuming and costly steps, including in vitro maturation of scFv sequence and/or recloning of scFv fused to immunoglobulin (Ig) constant regions. Mechanisms underlying the loss of scFv function include changes in scFv conformation and post-translational modifications, due to the use of different expression systems for displayed and secreted forms.
We sought to generate a highly efficient system for high-throughput identification of antigen-specific affinity reagents. Because patients with autoimmune disorders produce large variety of antibodies, we hypothesized that a library derived from an autoimmune patient could contain high-affinity antibodies against various antigens, including tumor vascular markers. We also hypothesized that only one expression system (Saccharomyces cerevisiae) for both scFv display and secretion could eliminate changes in scFv post-translational modifications, while keeping the advantages of a eukaryotic system for the expression of high-affinity antibodies, and that conformational changes would be minimized during the shift from displayed to secreted scFv forms if both displayed and secreted scFv were modified only at the N-terminus, which binds to the yeast surface or to secondary reagents, respectively. To test our hypotheses, we generated a 1 × 109 yeast-display scFv library by homologous recombination of our new vector pAGA2 with scFv amplified from a phage-display scFv library derived from a patient with thrombotic thrombocytopenic purpura (TTP), an autoimmune system disease related to the production of autoantibodies against coagulation factors (Siegel, 2008). We screened the TTP yeast-display scFv library in two steps using two complementary yeast systems of expression that permit to express yeast-display and yeast-secreted scFv with the same post-translational modifications while minimizing conformational changes. We identified several Endosialin/TEM1-specific scFv using human TEM1 recombinant protein, including one with affinity in the nanomolar range, that were further transformed in biobodies (Scholler et al., 2006). Antigen-specific binding of anti-TEM1 scFv and biobodies was characterized in vitro by flow cytometry analysis and ELISA assay, and in vivo by injection in an orthotopic mouse model of ovarian cancer. The anti-TEM1 biobody of highest affinity was able to bind specifically to both murine and human Endosialin/TEM1 and to target Endosialin/TEM1-expresser tumor cells in vivo, paving the way to the development of novel anti-angiogenesis targeted-theranostics.
Section snippets
Development of companion vectors for yeast-display and yeast secretion of N-terminal biotinylated scFv
The pAGA2 vector for yeast display (Fig. 1a–b) was derived from shuttle vector p414 GAL1 (Mumberg et al., 1994; the kind gift of Martin Funk, IMT, Philipps-Univ. Marburg, Germany). The pAGA2 multiple cloning site (MCS) was engineered as follows: the first site Nhe1 was inserted after a FLAG tag and a (G4S)3 linker sequence. The second site EcoR1 was part of a stop codon that is removed when cDNA is inserted in frame in the cloning site. The third site Xho1 was inserted just 5′ to the c-myc tag,
Generation of companion vectors for yeast display and yeast secretion of N-terminal biotinylated scFv
To overcome the loss of antigen specificity and/or affinity due to scFv transfer from cell surface display to secreted, we developed two complementary vectors, pAGA2 and p416 BCCP, which permit scFv to be displayed (Fig. 1a–b) or secreted (Fig. 1c–d) by the same expression system (S. cerevisiae) and through engineering at the same domain (N-terminus), thus with similar post-translational modifications and conformation. In pAGA2 vector, scFv are fused at the N-terminus to Aga2, to permit yeast
Discussion
We isolated high-affinity reagents (scFv and biobodies) that bound to both mouse and human Endosialin/TEM1, using a high-throughput yeast-based platform and a two-step screening method. Anti-TEM1 scFv and biobodies were validated for flow cytometry use, ELISA detection assays and in vivo targeting. The affinity of our novel anti-TEM1 biobody-78 was in the nanomolar range which permitted to generate high mean fluorescence intensities (MFI) by flow cytometry analysis at very low concentration (10
Conclusion
The foreseeable clinical and laboratory applications of fully human scFv and especially biobodies are quite diverse. We describe here for the first time a biobody (biobody-78) that can detect both human and mouse Endosialin/TEM1 for flow cytometry analysis and ELISA applications, and that is stable in vivo with intact functional binding 48 h after IV injection (Fig. 6C upper and lower right panels), permitting confocal analysis of harvested tissues. Therefore, biobody-based targeting of tumor
Competing interests statement
The authors declare no competing financial interests.
The following are the supplementary materials related to this article.
Acknowledgments
We acknowledge Yi Cheng and Lindsay Bergan for excellent technical assistance, John Facciaponte for help with the qRT-PCR assays, Carmine Carpenito for the preparation of lentiviruses from the pTurboFP635-C vector, Tony Secreto for assistance with orthotopic injections, and Ryan D. Wychowanec for flow sorting. The project described was first supported by the Pacific Ovarian Cancer Research Consortium, Award Number P50 CA083636 from the National Cancer Institute (Nicole Urban) and the Canary
References (43)
- et al.
Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay
J. Immunol. Meth.
(1987) - et al.
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment
Cancer Lett.
(2007) - et al.
Construction and diversification of yeast cell surface displayed libraries by yeast mating: application to the affinity maturation of Fab antibody fragments
Gene
(2004) - et al.
Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium
J. Biol. Chem.
(2001) - et al.
Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells
Am. J. Pathol.
(2008) - et al.
Vascular leukocytes contribute to tumor vascularization
Blood
(2005) Tumor angiogenesis
Adv. Cancer Res.
(1985)- et al.
Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium
FEBS Lett.
(2005) - et al.
Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy
Cancer Lett.
(2006) - et al.
Autoantibody profiling for cancer detection
Clin. Lab. Med.
(2009)
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating
J. Immunol. Meth.
The sentinel within: exploiting the immune system for cancer biomarkers
J. Proteome Res.
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
Mol. Cancer Ther.
Phage Display: A Laboratory Manual
Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K
FASEB J.
Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage
Protein Eng. Des. Sel.
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines
Lab. Investig.
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
Cancer Res.
Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer
Clin. Exp. Metastasis
Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin
Cancer Immun.
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library
Nat. Biotechnol.
Cited by (46)
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1
2021, Cell Reports MedicineCitation Excerpt :Initially, our investigations centered on whether an anti-TEM1 scFv could show functionality in a second-generation CAR format. To this end, the previously described anti-TEM1 scFv sc78 and a scFv derived from MORAb-004 (ontuxizumab) were incorporated into a modular second-generation CAR construct comprising the spacer, TM, and cytosolic domains of CD28 fused to CD3ζ ITAM signaling elements and an in-frame monomeric GFP reporter.37,41 Surprisingly, neither sc78 nor MORAb-004 scFv showed activity in this generic CAR context.
Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies
2021, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :TEM1 is a type I cell surface glycoprotein of 757 amino acids structurally related to thrombomodulin [12–15]. TEM1 expression is negligible in adult blood vessels however in several carcinomas TEM1 overexpression has been found in endothelial cells, pericytes and tumour-associated fibroblasts, indicating a role in vascular cell adhesion and migration, neoangiogenesis, tumour progression and metastatization [16–21]. A study conducted with TEM1 knock-out mice indicated that the absence of this protein did not affect overall health and normal wound healing.
Simple strategy for single-chain fragment antibody-conjugated probe construction
2019, Life SciencesCitation Excerpt :Tumor endothelium marker 1 (TEM1) is a novel surface marker for many solid tumors, including OC. Our group has successfully isolated and characterized the first fully human anti-TEM1 scFv (scFv78) [9,10]. In this paper, anti-TEM1 scFv was used for the evaluation of strategies for nanoparticle (SPIO) conjugation or fluorescence dye (ICG) conjugation.
Development of a modified yeast display system for screening antigen-specific variable lymphocyte receptor B in hagfish (Eptatretus burgeri)
2019, Journal of Immunological MethodsCitation Excerpt :The YD system offers several advantages: i) a eukaryotic expression system capable of post-translational modifications such as disulfide bond formation, ii) relatively low technical and time requirements compared with mammalian display systems, and iii) compatibility with fluorescence-activated cell sorting (FACS) which allows quantitative discrimination of desired clones within the libraries through simultaneous data analysis (Siegel et al., 2004). Various antibodies have been successfully developed using a YD platform against a variety of specific molecules, such as HIV-1 gp120, tuberculosis Antigen 85, epidermal growth factor receptor and the tumor vascular marker Endosialin/TEM1 (Chao et al., 2004; Walker et al., 2009; Zhao et al., 2011; Ferrara et al., 2012). Variable lymphocyte receptors (VLRs) are a unique form of immune receptors that mediate acquired immune systems in jawless vertebrates.
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma
2018, European Journal of Cancer
- 1
These authors equally contributed to the work.